Tonix Pharmaceuticals Holding (TNXP) 10-K2013 FY Annual report

Filed: 28 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abnormal, accuracy, adoptedauthoritative, ahead, Allergan, amitriptyline, analgesic, andthe, antagonist, apromissory, areconvertible, arrangement, aspirin, athree, Aug, Bay, Bayer, began, benzodiazepine, BESTFIT, biodefense, Biotie, breach, breached, Breakthrough, Brunswick, build, building, calcium, Campbell, cardiovascular, career, cGCP, chemo, Chimerix, clarified, Codeine, commercializecertain, Commissionon, complicated, component, comprehensive, contest, contraindication, counterpart, country, creation, credible, currency, death, deducting, diminution, disability, dishonesty, displaying, disrupted, dissolve, disulfiram, downgrade, draft, dropping, durable, duty, earnout, embezzlement, episodic, ETTH, eutectic, FDASIA, felony, female, field, FinancialAccounting, Fioricet, Fiorinal, footage, fortax, Francisco, geopolitical, geriatric, GershellAgreement, guilty, halt, headache, headcount, ibuprofen, Iglehart, illegal, IMH, immigration, incapacity, incidence, incident, indirectly, inflation, instability, Intervention, ionizing, Iredell, isolation, isomer, Journal, Kindred, LedermanAgreement, leisure, lengthened, live, living, long, loyalty, Lundbeck, man, manifest, membrane, memory, Midrin, MigraTen, mildly, misconduct, modulating, mucosal, mutually, naproxen, neglect, negligence, nerve, neuropsychiatric, nighttime, norepinephrine, notesin, notified, Nov, NuMedii, occupational, ofapproximately, OnJanuary, onJune, OnMarch, onmay, opiate, parallel, patentee, peri, peripheral, perspective, pharmacologic, pharmacology, PK, platform, plea, preliminary, Premier, preserve, prevailing, province, provisional, PSP, purified, purposesexpiring, pursuit, racemic, radiation, radio, radioprotection, ratably, reorganization, repeat, repeated, RiboCor, Roth, salivary, scalability, score, sedative, segment, selegiline, sensory, signaling, simultaneously, smallpox, SNARI, social, split, StandardsBoardwhich, Stereoisomeric, store, subscore, successor, symptomatic, tension, terrorism, thatexpire, theAgreement, theGershell, theLederman, threatening, throughthe, translated, translation, twopromissory, umbrella, unavailable, understood, undesirable, uninsured, unmet, unpaid, unreliable, unrest, unsatisfactory, vaccine, vaccinia, vascular, venlafaxine, viability, visibility, waiver, war, wasdeclared, whichexpire, withholding, workforce

Removed: broker, buy, closely, dealer, doubt, existence, maturity, minimal, penny, personal, promoter, prospect, proven, quotation, removal, renamed, resigned, seasoned, shell, suitability, TAEI, understanding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TNXP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.01

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ SETH LEDERMAN
Date: March 28, 2014	Name:	Seth Lederman
	Title:	Chief Executive Officer

I, Leland Gershell, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ LELAND GERSHELL
Date: March 28, 2014	Name:	Leland Gershell
	Title:	Chief Financial Officer